← Human Trials & Peer-Reviewed Studies
The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
Plain-language guide to PMID 20405138 (2010): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), parkinson's disease.
Key Facts
- PMID
- 20405138
- Journal
- Journal of neurology
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Zhang K et al. (5 authors)
- DOI
- 10.1007/s00415-010-5556-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of parkinson's disease in this randomized controlled trial publication.
This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD).
Twenty-four patients with MSA-p and 26 cases with PD entered the study.
Who Took Part
The age groups tagged for this paper are older adults, both men and women.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
The GH peak in serum at different times was evaluated and used as a primary variable for analysis of the stimulation test.
What Was Measured
This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD).
By ROC analysis, the researchers compared the sensitivity and specificity of tests of clonidine, arginine and both combined.
Topics PubMed links to this paper include Arginine, Clonidine, Diagnosis, Differential, Drug Combinations, Human Growth Hormone, Multiple System Atrophy and Parkinsonian Disorders.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in people with parkinson's disease.
The publication is from 2010 (Journal of neurology), a journal based in Germany.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Parkinson's disease research.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- Parkinson's disease research
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.